![Holger Jon Møller](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Holger Jon Møller
Oprichter bij DeLiver Pharma ApS
Actieve functies van Holger Jon Møller
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Affinicon ApS
![]() Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark. | Directeur/Bestuurslid | 15-06-2016 | - |
DeLiver Pharma ApS
![]() DeLiver Pharma ApS Pharmaceuticals: MajorHealth Technology DeLiver Pharma ApS manufactures pharmaceutical products. The firm carries on business with medical development and any related business. The company was founded on March 9, 2018 and is headquartered in Odense, Denmark. | Directeur/Bestuurslid | - | - |
Oprichter | - | - |
Loopbaan van Holger Jon Møller
Eerdere bekende functies van Holger Jon Møller
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Cytoguide ApS
![]() Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | Directeur/Bestuurslid | 03-05-2010 | 20-05-2014 |
Oprichter | 12-08-2009 | 20-05-2014 | |
Corporate Officer/Principal | 03-05-2010 | 20-05-2014 | |
IQ Products | Directeur/Bestuurslid | 12-08-2009 | - |
University of Aarhus | Corporate Officer/Principal | 12-08-2009 | - |
Opleiding van Holger Jon Møller
University of Aarhus | Doctorate Degree |
Statistieken
Internationaal
Denemarken | 5 |
Nederland | 2 |
Operationeel
Director/Board Member | 4 |
Founder | 2 |
Corporate Officer/Principal | 2 |
Sectoraal
Health Technology | 4 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 4 |
---|---|
Cytoguide ApS
![]() Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | Health Technology |
IQ Products | |
DeLiver Pharma ApS
![]() DeLiver Pharma ApS Pharmaceuticals: MajorHealth Technology DeLiver Pharma ApS manufactures pharmaceutical products. The firm carries on business with medical development and any related business. The company was founded on March 9, 2018 and is headquartered in Odense, Denmark. | Health Technology |
Affinicon ApS
![]() Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark. | Health Technology |
- Beurs
- Insiders
- Holger Jon Møller
- Ervaring